View More Recent Stories

May 11, 2020 04:05PM BeiGene Reports First Quarter 2020 Financial Results
Apr 29, 2020 05:00PM BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 20, 2020 04:15PM BeiGene (BGNE) Announces Acceptance of sNDA for Tislelizumab in Combination with Chemotherapy in First-Line Advanced NSCLC
Apr 20, 2020 04:05PM BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
Apr 13, 2020 04:07PM BeiGene (BGNE) Announces Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line NSCLC Met Primary Endpoint of PFS at Interim Analysis
Apr 13, 2020 04:05PM BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Sur
Apr 10, 2020 06:00PM China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Jan 2, 2020 08:17AM Amgen (AMGN) Commences Strategic Collaboration With BeiGene (BGNE) to Expand Oncology Presence in China
Nov 5, 2019 08:15AM BeiGene (BGNE). Seattle Genetics (SGEN) Report Global License Agreement for Advanced Preclinical Product Candidate
Nov 5, 2019 08:00AM Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate
Oct 31, 2019 04:01PM Amgen (AMGN) will acquire 20.5% stake in BeiGene (BGNE) for approximately $2.7 billion in cash
Mar 1, 2018 08:39AM BIO-Europe Spring(R) 2018 comes to Amsterdam in less than two weeks
Dec 7, 2016 07:54AM Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics
Jun 22, 2016 07:30AM Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Apr 20, 2016 10:00AM BeiGene (Nasdaq: BGNE) to Ring The Nasdaq Stock Market Opening Bell
View More Recent Stories